154 related articles for article (PubMed ID: 28351392)
1. Can we use gonadotropin plasma concentration as surrogate marker for BMI-related incomplete estrogen suppression in breast cancer patients receiving anastrozole?
Oberguggenberger A; Meraner V; Sztankay M; Beer B; Weigel G; Oberacher H; Kemmler G; Czech T; Holzner B; Wildt L; Sperner-Unterweger B; Daniaux M; Hubalek M
BMC Cancer; 2017 Mar; 17(1):226. PubMed ID: 28351392
[TBL] [Abstract][Full Text] [Related]
2. Does obesity interfere with anastrozole treatment? Positive association between body mass index and anastrozole plasma levels.
Hubalek M; Oberguggenberger A; Beer B; Meraner V; Sztankay M; Oberacher H; Schubert B; Wildt L; Seeber B; Giesinger J; Kemmler G; Holzner B; Sperner-Unterweger B
Clin Breast Cancer; 2014 Aug; 14(4):291-6. PubMed ID: 24468298
[TBL] [Abstract][Full Text] [Related]
3. Impact of BMI on serum estradiol and bone turnover markers in postmenopausal women with hormone-sensitive early breast cancer treated with anastrozole.
Kyvernitakis I; Knöll D; Struck M; Hars O; Bauer T; Hadji P
J Cancer Res Clin Oncol; 2014 Jan; 140(1):159-66. PubMed ID: 24292402
[TBL] [Abstract][Full Text] [Related]
4. Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer.
Folkerd EJ; Dixon JM; Renshaw L; A'Hern RP; Dowsett M
J Clin Oncol; 2012 Aug; 30(24):2977-80. PubMed ID: 22802308
[TBL] [Abstract][Full Text] [Related]
5. Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors.
Lønning PE; Haynes BP; Dowsett M
Eur J Cancer; 2014 Apr; 50(6):1055-64. PubMed ID: 24507547
[TBL] [Abstract][Full Text] [Related]
6. Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer.
Pfeiler G; Königsberg R; Hadji P; Fitzal F; Maroske M; Dressel-Ban G; Zellinger J; Exner R; Seifert M; Singer C; Gnant M; Dubsky P
Br J Cancer; 2013 Sep; 109(6):1522-7. PubMed ID: 24002592
[TBL] [Abstract][Full Text] [Related]
7. Estrone and Estradiol Levels in Breast Cancer Patients Using Anastrozole Are Not Related to Body Mass Index.
Coscia EB; Sabha M; Gerenutti M; Groppo FC; Bergamaschi CC
Rev Bras Ginecol Obstet; 2017 Jan; 39(1):14-20. PubMed ID: 28187491
[No Abstract] [Full Text] [Related]
8. [Effects of anastrozole on lipid metabolism in Chinese postmenopausal women with breast cancer].
Lu HH; Li Q; Xu BH; Zhang P; Yuan P; Wang JY; Cai RG
Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):520-5. PubMed ID: 22093630
[TBL] [Abstract][Full Text] [Related]
9. Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels.
Geisler J; Helle H; Ekse D; Duong NK; Evans DB; Nordbø Y; Aas T; Lønning PE
Clin Cancer Res; 2008 Oct; 14(19):6330-5. PubMed ID: 18829517
[TBL] [Abstract][Full Text] [Related]
10. Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole.
Ingle JN; Kalari KR; Buzdar AU; Robson ME; Goetz MP; Desta Z; Barman P; Dudenkov TT; Northfelt DW; Perez EA; Flockhart DA; Williard CV; Wang L; Weinshilboum RM
Steroids; 2015 Jul; 99(Pt A):32-8. PubMed ID: 25163006
[TBL] [Abstract][Full Text] [Related]
11. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.
Geisler J; King N; Dowsett M; Ottestad L; Lundgren S; Walton P; Kormeset PO; Lønning PE
Br J Cancer; 1996 Oct; 74(8):1286-91. PubMed ID: 8883419
[TBL] [Abstract][Full Text] [Related]
12. Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer.
Miller WR; Stuart M; Sahmoud T; Dixon JM
Br J Cancer; 2002 Oct; 87(9):950-5. PubMed ID: 12434282
[TBL] [Abstract][Full Text] [Related]
13. Effect of tamoxifen or anastrozole on steroid sulfatase activity and serum androgen concentrations in postmenopausal women with breast cancer.
Stanway SJ; Palmieri C; Stanczyk FZ; Folkerd EJ; Dowsett M; Ward R; Coombes RC; Reed MJ; Purohit A
Anticancer Res; 2011 Apr; 31(4):1367-72. PubMed ID: 21508387
[TBL] [Abstract][Full Text] [Related]
14. Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer.
Geisler J; Detre S; Berntsen H; Ottestad L; Lindtjørn B; Dowsett M; Einstein Lønning P
Clin Cancer Res; 2001 May; 7(5):1230-6. PubMed ID: 11350888
[TBL] [Abstract][Full Text] [Related]
15. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.
Dixon JM; Renshaw L; Young O; Murray J; Macaskill EJ; McHugh M; Folkerd E; Cameron DA; A'Hern RP; Dowsett M
J Clin Oncol; 2008 Apr; 26(10):1671-6. PubMed ID: 18375896
[TBL] [Abstract][Full Text] [Related]
16. Obesity and endocrine therapy: host factors and breast cancer outcome.
Goodwin PJ
Breast; 2013 Aug; 22 Suppl 2():S44-7. PubMed ID: 24074791
[TBL] [Abstract][Full Text] [Related]
17. Biological activity of anastrozole in postmenopausal patients with advanced breast cancer: effects on estrogens and bone metabolism.
Bajetta E; Martinetti A; Zilembo N; Pozzi P; La Torre I; Ferrari L; Seregni E; Longarini R; Salvucci G; Bombardieri E
Ann Oncol; 2002 Jul; 13(7):1059-66. PubMed ID: 12176784
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index.
Sendur MA; Aksoy S; Zengin N; Altundag K
Br J Cancer; 2012 Nov; 107(11):1815-9. PubMed ID: 23099804
[TBL] [Abstract][Full Text] [Related]
19. Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer.
Bender CM; Sereika SM; Brufsky AM; Ryan CM; Vogel VG; Rastogi P; Cohen SM; Casillo FE; Berga SL
Menopause; 2007; 14(6):995-8. PubMed ID: 17898668
[TBL] [Abstract][Full Text] [Related]
20. Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole.
Prowell TM; Blackford AL; Byrne C; Khouri NF; Dowsett M; Folkerd E; Tarpinian KS; Powers PP; Wright LA; Donehower MG; Jeter SC; Armstrong DK; Emens LA; Fetting JH; Wolff AC; Garrett-Mayer E; Skaar TC; Davidson NE; Stearns V
Cancer Prev Res (Phila); 2011 Dec; 4(12):1993-2001. PubMed ID: 21885816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]